Skip to main content
. 2024 Feb 12;4(2):378–387. doi: 10.1158/2767-9764.CRC-22-0260

TABLE 2.

Tumor response according to RECIST v1.1 (investigator assessment) in response-evaluable patients

Best confirmed response Number of patients
Partial response (PR) 4 (13%)
Stable disease (SD) 15 (50%)
Progressive disease (PD) 5 (17%)
Not evaluable 6 (20%)